How I manage mantle cell lymphoma: indolent versus aggressive disease.
Wilson MR, Barrett A, Cheah CY, Eyre TA.
Br J Haematol. 2023 Apr;201(2):185-198. doi: 10.1111/bjh.18697. Epub 2023 Feb 20.
Non-Hodgkin lymphoma.
Armitage JO, Gascoyne RD, Lunning MA, Cavalli F.
Lancet. 2017 Jul 15;390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2. Epub 2017 Jan 31.
PET/CT in Non-Hodgkin Lymphoma: An Update.
Zanoni L, Bezzi D, Nanni C, Paccagnella A, Farina A, Broccoli A, Casadei B, Zinzani PL, Fanti S.
Semin Nucl Med. 2023 May;53(3):320-351. doi: 10.1053/j.semnuclmed.2022.11.001. Epub 2022 Dec 14.
Lymphoma.
Mugnaini EN, Ghosh N.
Prim Care. 2016 Dec;43(4):661-675. doi: 10.1016/j.pop.2016.07.012.
Lymphoma Classification.
de Leval L, Jaffe ES.
Cancer J. 2020 May/Jun;26(3):176-185. doi: 10.1097/PPO.0000000000000451.
[Treatment of indolent cutaneous B-cell lymphoma].
Wobser M.
Hautarzt. 2017 Sep;68(9):721-726. doi: 10.1007/s00105-017-4022-4.
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Leslie LA.
Curr Treat Options Oncol. 2021 Oct 25;22(12):111. doi: 10.1007/s11864-021-00909-1.
Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia.
Shah PS, Jacobson CA.
Hematol Oncol Clin North Am. 2023 Dec;37(6):1077-1088. doi: 10.1016/j.hoc.2023.07.002. Epub 2023 Aug 31.
Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.
Jiang M, Bennani NN, Feldman AL.
Expert Rev Hematol. 2017 Mar;10(3):239-249. doi: 10.1080/17474086.2017.1281122. Epub 2017 Jan 29.
Indolent pediatric lymphomas/lymphoproliferative disorders: a report of the 2024 EA4HP/SH lymphoma workshop.
Frauenfeld L, Ponzoni M, Gasljevic G, Anagnostopoulos I, Van den Brand M, Cook JR, Laurent C, Sander B, Dirnhofer S, Quintanilla-Martinez L, Balague O.
Virchows Arch. 2025 Aug;487(2):309-325. doi: 10.1007/s00428-025-04184-5. Epub 2025 Jul 23.
